Background: Recent therapeutic advances such as immune checkpoint inhibitors (ICIs) have impact on the care of non-small cell lung cancer (NSCLC) patients, however, they bring new setbacks for regulatory agencies.
Objective: To evaluate the regulatory journey of ICIs registered for NSCLC treatment in Brazil and to establish comparisons of Brazilian regulatory agency with the US regulatory agency.
Methods and data source: Information for each ICI prescribing as well as the date of regulatory approval of the therapeutic indications of interest were collected from the Anvisa and the FDA websites. The search took place on October 2022.
Key findings: There are only 20 % disagreements on regulatory approvals between Anvisa and FDA. The prioritization review at Anvisa in 2008 has made the regulatory assessment faster.
Conclusions: The results of this study identified a potential improvement in Anvisa's time performance to connect the target established by the legal framework of the sector.
Keywords: Anvisa; FDA; Immune checkpoint inhibitors; Non-small cell lung cancer; Regulatory approval.
Copyright © 2023 Elsevier B.V. All rights reserved.